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Abstract: Ceramide transfer protein (CERT) mediates non-
vesicular transfer of ceramide from endoplasmic reticulum
to Golgi apparatus and thus catalyzes the rate-limiting
step of sphingomyelin biosynthesis. Usually, CERT ligands
are evaluated in tedious binding assays or non-homoge-
nous transfer assays using radiolabeled ceramides. Herein,
a facile and sensitive assay for CERT, based on Fçrster res-
onance energy transfer (FRET), is presented. To this end,
we mixed donor and acceptor vesicles, each containing a
different fluorescent ceramide species. By CERT-mediated
transfer of fluorescent ceramide, a FRET system was estab-
lished, which allows readout in 96-well plate format, de-
spite the high hydrophobicity of the components. Screen-
ing of a 2 000 compound library resulted in two new
potent CERT inhibitors. One is approved for use in
humans and one is approved for use in animals. Evalua-
tion of cellular activity by quantitative mass spectrometry
and confocal microscopy showed inhibition of ceramide
trafficking and sphingomyelin biosynthesis.
Cellular homeostasis is the result of multiple, regulated meta-
bolic pathways that may be over- or under-represented in
pathological contexts. Pharmacological influence on metabo-
lite concentrations is usually achieved by inhibition of rate-lim-
iting enzymes of a given pathway. However, rate-limiting en-
zymes for most metabolic pathways have been identified in
the past from cell lysates or with purified enzymes, at the ex-
pense of topological information. While topological consider-
ations may be simple for pathways converting soluble sub-
strates, they are crucial and complex for lipid substrates. By
definition, lipids are not water-soluble and transitions between
different membranes require either complex vesicular transport
mechanisms or specific transport proteins.[1] Like many other
biosynthetic pathways, the biosynthesis of sphingolipids ex-
tends throughout the membranes of different organelles,
which makes specific transport processes essential compo-
nents of the individual pathway.[2] A growing body of evidence
suggests that such transport processes are the rate-limiting
steps of the whole sphingolipid biosynthetic pathway and
sphingolipid transport proteins are now considered as pharma-
cological target molecules.[3]
Sphingolipids constitute an abundant and ubiquitous class
of lipids in eukaryotic organisms. Their biosynthesis starts with
the condensation of serine and palmitoyl CoA in the cytosolic
leaflet of the endoplasmic reticulum (ER) membranes.[4] In
three further steps, ceramide is formed, which serves as the
membrane anchor for the more complex sphingolipids, like
glycosphingolipids (GSL) or sphingomyelin (SM), a major com-
ponent of eukaryotic plasma membranes. However, since syn-
thesis of the latter takes place in different sub-compartments
of the Golgi apparatus (Golgi), ceramide must be transported
from the ER membrane to the membranes of the Golgi appara-
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tus. Recently, it has been shown that non-vesicular transport of
ceramide from ER to Golgi is mediated by the ceramide trans-
port protein (CERT) and that this transporter represents the
rate-limiting step for the biosynthesis of sphingomyelin.[5] In
fact, malfunctioning of the CERT protein leads to various path-
ologies[6] and inhibition of this transporter has shown promis-
ing results in experimental therapies for the treatment of
cancer,[7] hepatitis C virus (HCV)[8] or chlamydia infections.[9]
Some time ago, the ceramide analogue HPA-12 was developed
as a potent inhibitor of CERT.[10] Co-crystal structures of the
START domain of CERT together with ceramide or HPA-12 have
been published[11] and numerous studies have been carried
out to find an efficient synthesis for the inhibitor[12] or an im-
provement of its structure.[13] Indeed, improvements of affinity
to the START domain have been achieved in cell-free systems.
In most cases, complex assays were employed, in which a fluo-
rescence-labeled ceramide was used for competitive binding
experiments with subsequent pull-down of the CERT protein.
Binding affinity is defined by the quotient of the ceramide
fluorescence from the supernatant and from the CERT-pull-
down fraction.[14] Alternatively, liposomal transfer of radiola-
beled ceramide between donor and acceptor liposomes is pos-
sible.[15] The acceptor liposomes are pulled down by a bead-
bound lectin, since only the acceptor liposomes contain a
lectin ligand, glucosylceramide. Subsequently, quantification of
the transfer is calculated by radiometric measurements of the
two different fractions. Recently, a fluorescence-based assay of
ceramide transfer has also been described, in which a fluores-
cently labeled ceramide is transferred to liposomes containing
a quencher lipid.[16] This assay was performed in cuvettes, but
miniaturization has not been described yet, probably due to
low transfer rates. The fact that ceramide is one of the most
hydrophobic mammalian lipids is a primary obstacle and the
use of detergents in liposome-based applications is contraindi-
cated. Because of these difficulties and the urgent need for
more drug-like CERT inhibitors, a virtual screening has recently
been performed, taking advantage of the well-known 3D bind-
ing mode of the HPA-12 inside CERT’s START domain. A lead
identified in this process showed a KD of 11 mm, which after op-
timization could be improved to 60 nm. The cellular activity of
the final compound was comparable to HPA-12, making it the
first non-ceramide analogue inhibitor of CERT.[17] However,
nothing is known about the compounds toxicity or whether it
is applicable to experiments in mice or humans. Despite the
great success of this approach, we reasoned that the search
for compounds that mimic an already known binding mode
would reveal only a fraction of the possible inhibitors. We
therefore aimed at developing a screening assay that should
be as realistic as possible in order to be able to detect com-
pounds with completely new binding modes. We reasoned
that in any case, a transfer assay would be more predictive
than a binding assay. Being inspired by our recent success in
developing assays of sphingolipid metabolizing enzymes
based on Fçrster Resonance Energy Transfer (FRET),[18] we
wanted to apply this principle to a CERT-mediated lipid trans-
fer assay. The goal was to monitor the activity of CERT in a ho-
mogeneous assay system in multi-well format and making use
of the inherent normalization of fluorescence by dual wave-
length readout.[19] The idea was that perhaps a bi-directional
transfer of dye-labelled ceramides could achieve the necessary
transfer rate. For this purpose, we used fluorescent dyes,
which we had proven to be effective in our previous FRET
probes. Hence, a coumarin ceramide (MCC-Cer) and an NBD
ceramide (NBD-Cer) were synthesized,[20] respectively, and em-
bedded into separate liposomes (Figure 1).
When coumarin was excited (lEx = 347 nm), the correspond-
ing fluorescence (lEm = 405 nm) could be observed, whereas
no significant fluorescence for NBD (lEm = 536 nm) could be
observed. However, after addition of recombinant human
CERT, an increase in NBD fluorescence occurred rapidly. The
curve changed to a plateau after some time, indicating a termi-
nation of the net transfer. The final increase in NBD fluores-
cence was up to 4fold. Somewhat unexpectedly, the coumarin
fluorescence did not change significantly, indicating that over-
all only a small fraction of the coumarin fluorescence energy
was transferred to NBD. The specificity of the NBD fluorescence
change was verified by different concentrations of CERT and
the possibility of inhibition by HPA-12 (see Supporting Infor-
mation for details). Transfer of this assay into 96-well plates
showed the same results without significant loss of lipid trans-
fer activity. To test the hypothesis of bidirectional transfer, one
of the two ceramide derivatives was successively replaced by a
non-transferable lipid carrying the same dye. Replacement of
coumarin ceramide showed the same results as above, while
the replacement of NBD ceramide by non-transferrable NBD-
lipid resulted in the absence of any fluorescence change (data
not shown). We therefore concluded that NBD ceramide (NBD-
Cer) but not coumarin ceramide (MCC-Cer) is transferred by
CERT. Having established a feasible miniaturized CERT assay, we
aimed to perform a limited screening for possible inhibitors.
However, the absence of transfer the short excitation wave-
length of coumarin seemed to us unfavorable, since many aro-
matic compounds show a significant absorption at such a
short wavelength. This would interfere with our screening
assay. Since we showed the transferability of NBD ceramide,
we considered making this lipid the FRET donor and providing
it with a suitable acceptor lipid. For this scenario, Nile red (NR)
emerged as a suitable partner and therefore, a NR- ceramide
was synthesized, accordingly.[21] Fortunately, also with this ce-
ramide FRET pair an assay in 96 well format could be success-
fully established. Moreover, in an experiment, similar to the
one described above, we observed transfer of NR-ceramide in
presence of non-transferrable NBD-lipid, which was inhibited
in the presence of the inhibitor HPA-12. Finally, a library of
2 000 compounds with proven pharmacological and/or biologi-
cal activity was tested at a concentration of 10 mm. Significant
inhibition—defined by inhibition like 1 mm HPA-12 or better—
yielded a total of 45 primary hits. Dose-response evaluation for
these hits and sorting out of compounds whose structures did
not indicate any promising further development, resulted in a
total of 9 compounds that were considered promising and
which were further investigated. The inhibitory effects were
found to be highly reproducible, with the exact values show-
ing some variation for different batches of the liposome prepa-




ration. For each assay, HPA-12 was therefore used as a refer-
ence substance. The assay established by us is in principle an
enzyme-catalyzed mixing of separate lipid pools and is there-
fore potentially interfered by substances that stimulate vesicle
fusion. Such compounds were expected to give false negative
results (no inhibition), although a number of compounds with
detergent-like properties showed inhibition, contrary to this
hypothesis. Nonetheless, we aimed at further investigation,
using orthogonal assays devoid of liposomes in order to proof
the validity of our approach. The binding assays described so
far seemed to us very complex and tedious for dose-response
studies. Therefore, we considered using the environmental sen-
sitivity of the existing dye-labeled ceramides for a competitive
assay. Nile red is known to show strongest fluorescence in a
non-polar environment, therefore we suspected that Nile red
ceramide bound to a hydrophobic pocket of CERT would be
much more fluorescent than in the unbound state. To test this
hypothesis, a 1 mm micellar solution of Nile red ceramide was
treated with increasing concentrations of CERT. In fact, an up
to 20-fold increase in fluorescence was observed, which could
be reverted to approximately the initial value using HPA-12.
Notably, this effect was much less pronounced using the less
active R,R diastereomer of HPA-12 (see Figure S8). Hence, the
fluorescence of Nile red ceramide is therefore a suitable tool to
evaluate competitive CERT binders in a homogenous fashion.
After the NR ceramide competition assay, four compounds
were selected for further evaluation in cells. Three compounds,
8E8, 20D5 and 6B11 showed high activity in both, the transfer
and the competition assay (Figure 2 B&C). Furthermore, we se-
lected 17C9, which showed a weak dose-response in the trans-
fer assay, but a very strong competition to the binding of NR
ceramide. Finally, we fluorescently labeled the recombinant
START domain of CERT and monitored binding to the candi-
date compounds, using microscale thermophoresis (MST). For
HPA-12, a KD of &40 nm was determined, which is in rather
good agreement with KD values determined in a recently de-
veloped surface plasmon resonance assay, in which the START
domain was immobilized on solid phase.[17] Our new solution
phase MST-based binding assay confirmed binding for all com-
pounds except 17C9, but the affinities for 8E8 (KD&5 mm),
20D5 (KD&150 mm) and 6B11 (KD&5 mm) were significantly
lower than for HPA-12 (Figure S6). This could reflect different
binding modes to CERT, which may include components other
than the START domain.
Finally, we tested the activity of these compounds in cell-
based assays (Figure 3). For this purpose, HeLa cells were incu-
bated with the identified compounds or HPA-12 for 48 hours
in a serum-reduced medium, and the effect on individual
sphingolipid species was analyzed by quantitative mass spec-
trometry.[22] Indeed, 8E8 and 20D5 showed a dose-dependent
reduction of total sphingomyelin, while treatment with 6B11 or
17C9 showed no significant changes in total sphingomyelin.
Compared to HPA-12, 20D5 showed a similar total sphingo-
myelin for all concentrations used. In contrast, 8E8 showed
lower effects than HPA-12 at lower concentrations, but a dras-
tic reduction of sphingomyelin at 5 mm. In addition, relation of
total sphingomyelin to ceramide showed much clearer dose
dependencies for both 20D5 and 8E8 and an increased poten-
Figure 1. CERT-mediated transfer assay. A) CERT mediates ER to Golgi transport of ceramide and thus biosynthesis of sphingomyelin by sphingomyelin syn-
thase (SMS). B) Concept of transfer assay. Two types of liposomes are mixed, each containing a differently labeled ceramide. CERT mediated transfer of NBD-
ceramide establishes a FRET system consisting of either coumarin-ceramide/NBD-ceramide or NBD-ceramide/Nile red ceramide. C) Structures of lipid species
and maximum excitation and emission wavelengths. Dashed arrows indicate possible FRET.




Figure 2. In vitro assays. A) Typical time course of the MCC-Cer/NBD-Cer transfer assay. Change of fluorescence intensity of NBD-Cer (lEm = 535 nm) after exci-
tation at 350 nm (MCC). Black squares: without CERT; blue triangles: in presence of CERT. Assay results were usually taken after 30 or 45 minutes and defined
by a reduction in total fluorescence at the respective time point, compared to the reaction without inhibitor. B) Transfer assay (NBD-Cer/NR-Cer) results for
final hits plus HPA-12. C) Results of NR-ceramide fluorescence competition assay. D) Structures of final compounds.
Figure 3. Cellular activity of hit compounds. A) Effects on cellular content of sphingomyelin (500 000 cells per sample). B) Effects on cellular ratios of total
sphingomyelin/ total ceramide. C) Effect on cellular staining by BODYPY FL ceramide. Asterisks indicate significant differences between samples calculated by
student’s t test. [*] p<0.05; [**] p<0.01; [***] p<0.005.




cy for 8E8 over all concentrations compared to HPA-12 and
similar or higher potency for 20D5. For the compounds finally
investigate, the transfer assay was more predictive for the re-
duction in SM biosynthesis, than the NR-ceramide competition
assay. Surprisingly, 6B11 and 17C9 led to a dramatically in-
creased SM/Cer rate, which was due to a reduction of almost
all ceramide species investigated. At present we do not have a
conclusive explanation for this behavior, but a future investiga-
tion of this phenomenon could be interesting.
Because all substances used were compounds with known
biological activity, it cannot be excluded that the observed
changes in the sphingolipidome are due to indirect effects. To
test the hypothesis that the identified compounds actually in-
hibit transport of ceramide in living cells, we treated HeLa cells
with fluorescence-labelled ceramide (BODIPY-Cer) in the pres-
ence of the four final compounds and examined the effects by
confocal microscopy. In fact, 6B11 and 17C9 showed only
minor effects and resembled the untreated controls, but com-
pounds 8E8 and 20D5 significantly influenced the intracellular
distribution of BODIPY-Cer (Figure 3 C and Figures S10&S11).
While the phenotype induced by 20D5 resembled that of HPA-
12, there was a major change in phenotype induced by 8E8.
20D5 (Fluralaner) is used in veterinary medicine and targets ar-
thropod parasite chloride channels and has no known target in
mammals.[23] In contrast, 8E8 (lomitapide) is targeting the
human microsomal triglyceride transfer protein (MTTP).[24] This
protein is located in the ER lumen and catalyzes the loading of
triglycerides, cholesterol esters and phospholipids into lipopro-
teins.[25] It has been shown that MTTP deficiency reduces
plasma levels of ceramide and to a lesser extend of sphingo-
myelin and that the purified protein is capable of transferring
radioactively labeled sphingomyelin and ceramide between
liposomes.[26] Based on our results that these molecules also in-
teract with purified human CERT and inhibit CERT-mediated ce-
ramide transfer, we established binding models for these com-
pounds by molecular docking and molecular dynamics (MD)
simulations.
MD simulations revealed that the CERT START domain in apo
form could close-open at the W1 loop (Figure 4 A). The W1
loop showed high temperature factors in the crystal struc-
ture[27] and might act as a gate for ligand binding. Both, 8E8
(lomitapide) and 20D5 (Fluralaner) maintained stable binding
in the ceramide-binding pocket, with some fluctuations near
the highly mobile W1 loop. Their amide group mimicked that
of the ceramide to form a hydrogen bond with residue Y553
(Figure 4 B and 4C). However, the affinity was mostly attributed
to hydrophobic interactions, especially with Y576 and F579
(see Figure S7 for key interactions and binding energies). In ad-
dition, 8E8 bound ionically with E446 and had significantly
lower binding free energy (@26.3:14.5 kcal mol@1) than 20D5
(@8.3:6.8 kcal mol@1), which may account for the stronger in-
hibitions by 8E8.
In summary, we have developed a new FRET-based ceramide
transfer assay to identify new CERT inhibitors. For two of these
compounds, we showed effective inhibition of CERT-mediated
transfer in vitro, replacement of CERT-bound Nile red ceramide
and interaction with the fluorescently labeled START domain of
CERT by MST. Finally, two compounds resulted in an increase
Figure 4. Representative conformations from the MD simulations. A) CERT START in apo form displayed transient (15 % of simulation time) opening at the W1
loop. B), C) Binding pose of 20D5 (fluralaner) and 8E8 (lomitapide) superimposed on C16-ceramide (black line).




of cellular ceramide at the expense of sphingomyelin concen-
trations. These two compounds were significantly more active
than HPA-12 at higher concentrations (5 mm). Moreover, confo-
cal microscopy of treated cells revealed that the compounds
altered ceramide trafficking. Noteworthy, these compounds are
approved for pharmacological use in humans (Lomitapide) or
animals (Fluralaner). By modelling the identified structures into
the START domain of CERT, we established a conclusive bind-
ing model, which may be used for structure-guided design of
future CERT inhibitors with increased affinity and selectivity.
Our results motivate to screening of larger libraries and to
apply the principles developed here to further lipid transferas-
es of biomedical interest.
Acknowledgements
This study was partially funded by the Deutsche Forschungsge-
meinschaft (AR 376/10-1 to C.A.). D.S. is grateful for a fellow-
ship provided by the Government of Egypt. E.M.S is grateful
for support by the EXIST program of the BMBF. :.A. is grateful
for a scholarship provided by School of Analytical Sciences
Adlershof (SALSA), funded by excellency initiative of the DFG.
We thank Pouria Asjodi for excellent technical assistance in
CERT purification and inhibitor screening. We thank Daniel
Herrmann for his technical assistance with the sphingolipido-
mics analyses. Open access funding enabled and organized by
Projekt DEAL.
Conflict of interest
The authors declare no conflict of interest.
Keywords: enzyme assays · Fçrster resonance energy transfer
(FRET) · liposomes · sphingolipids · transport proteins
[1] L. H. Wong, A. T. Gatta, T. P. Levine, Nat. Rev. Mol. Cell Biol. 2019, 20, 85 –
101.
[2] T. Yamaji, K. Hanada, Traffic 2015, 16, 101 – 122; J. C. Holthuis, A. K.
Menon, Nature 2014, 510, 48 – 57; L. H. Wong, A. Copic, T. P. Levine,
Trends Biochem. Sci. 2017, 42, 516 – 530.
[3] D. Samaha, H. H. Hamdo, M. Wilde, K. Prause, C. Arenz, Int. J. Mol. Sci.
2019, 20, 3554.
[4] T. Kolter, K. Sandhoff, Angew. Chem. Int. Ed. 1999, 38, 1532 – 1568;
Angew. Chem. 1999, 111, 1632 – 1670.
[5] K. Hanada, K. Kumagai, S. Yasuda, Y. Miura, M. Kawano, M. Fukasawa, M.
Nishijima, Nature 2003, 426, 803 – 809.
[6] X. Wang, R. P. Rao, T. Kosakowska-Cholody, M. A. Masood, E. Southon, H.
Zhang, C. Berthet, K. Nagashim, T. K. Veenstra, L. Tessarollo, U. Acharya,
J. K. Acharya, J. Cell Biol. 2009, 184, 143 – 158.
[7] A. J. Lee, R. Roylance, J. Sander, P. Gorman, D. Endesfelder, M. Kschischo,
N. P. Jones, P. East, B. Nicke, S. Spassieva, L. M. Obeid, N. J. Birkbak, Z.
Szallasi, N. C. McKnight, A. J. Rowan, V. Speirs, A. M. Hanby, J. Down-
ward, S. A. Tooze, C. Swanton, J. Pathol. 2012, 226, 482 – 494.
[8] Y. Amako, G. H. Syed, A. Siddiqui, J. Biol. Chem. 2011, 286, 11265 – 11274.
[9] C. A. Elwell, S. Jiang, J. H. Kim, A. Lee, T. Wittmann, K. Hanada, P. Melan-
con, J. N. Engel, PLoS Pathog. 2011, 7, e1002198; S. Koch-Edelmann, S.
Banhart, E. M. Saied, L. Rose, L. Aeberhard, M. Laue, J. Doellinger, C.
Arenz, D. Heuer, Cell. Microbiol. 2017, 19, e12752.
[10] S. Yasuda, H. Kitagawa, M. Ueno, H. Ishitani, M. Fukasawa, M. Nishijima,
S. Kobayashi, K. Hanada, J. Biol. Chem. 2001, 276, 43994 – 44002.
[11] N. Kudo, K. Kumagai, N. Tomishige, T. Yamaji, S. Wakatsuki, M. Nishijima,
K. Hanada, R. Kato, Proc. Natl. Acad. Sci. USA 2008, 105, 488 – 493.
[12] E. M. Saied, S. Diederich, C. Arenz, Chem. Asian J. 2014, 9, 2092 – 2094;
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